A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation

A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation is a phase 1/2, interventional study registered as NCT07752875 by LG Chem, with a registry enrolment figure of 250 participants, started 2026-12-01 and due to reach its primary completion in 2032-10-31. Interventions recorded: LG00313112. Conditions listed: Ovarian Cancer; Small Cell Lung Cancer; Non Small Cell Lung Cancer; Colorectal Cancer; Esophageal Cancer; Breast Cancer; Endometrial Cancer; Head and Neck Cancer; Pancreatic Cancer; Locally Advanced Unresectable or Metastatic Solid Tumor. Primary outcome: Phase 1: Number of participants with dose-limiting toxicities (DLTs); Phase 1: Frequency of treatment-emergent adverse events (TEAEs); Phase 1: Frequency of serious adverse events (SAEs). Pancreatic eligibility wording from the registry: "Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease". No results are recorded here; the registry entry is the source.